423 related articles for article (PubMed ID: 24562706)
1. [Current results on PSA-based prostate cancer detection].
Graefen M; Schlomm T; Steuber T; Sauter G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
[TBL] [Abstract][Full Text] [Related]
2. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
3. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
Duffy MJ
Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
[TBL] [Abstract][Full Text] [Related]
5. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
McDonald ML; Parsons JK
Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for early prostate cancer detection.
Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric MRI in the PSA screening era.
George AK; Pinto PA; Rais-Bahrami S
Biomed Res Int; 2014; 2014():465816. PubMed ID: 25250323
[TBL] [Abstract][Full Text] [Related]
9. [Focus on the screening for prostate cancer by PSA].
Roumeguère T; Van Velthoven R
Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen screening: pro.
Loeb S; Catalona WJ
Curr Opin Urol; 2010 May; 20(3):185-8. PubMed ID: 20224413
[TBL] [Abstract][Full Text] [Related]
11. [PSA screening 2013: background and perspectives].
Recker F; Seiler D; Seifert B; Randazzo M; Kwiatkowski M
Urologe A; 2014 Jun; 53(6):875-81. PubMed ID: 23712424
[TBL] [Abstract][Full Text] [Related]
12. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
[TBL] [Abstract][Full Text] [Related]
13. Early detection, PSA screening, and management of overdiagnosis.
Borza T; Konijeti R; Kibel AS
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
[TBL] [Abstract][Full Text] [Related]
14. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
Carter HB
BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
[TBL] [Abstract][Full Text] [Related]
15. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer: measuring PSA.
Pezaro C; Woo HH; Davis ID
Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
18. Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing.
Lavallée LT; Binette A; Witiuk K; Cnossen S; Mallick R; Fergusson DA; Momoli F; Morash C; Cagiannos I; Breau RH
Mayo Clin Proc; 2016 Jan; 91(1):17-22. PubMed ID: 26688045
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
[TBL] [Abstract][Full Text] [Related]
20. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
